Does carvedilol improve outcomes compared to metoprolol tartrate in patients with chronic heart failure, regardless of achieved heart rate, blood pressure, and beta-blocker dose?
The superiority of carvedilol over metoprolol tartrate in chronic heart failure is maintained regardless of the achieved heart rate, systolic blood pressure, or beta-blocker dose.
Beta-blocker dose, HR, and SBP achieved during beta-blocker therapy have independent prognostic value in heart failure. None of these factors influenced the beneficial effects of carvedilol when compared with metoprolol tartrate at the pre-defined target doses used in COMET.
Metra et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: